§ Federal grant opportunity · PAR-28-022
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
National Institutes of Health is accepting applications for Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required). The deadline is September 25, 2029 and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- September 25, 2029
- Award range
- Award amount not published
- Eligibility
- federally recognized native american tribal governments, other native american tribal organizations, public and indian housing authorities, state governments, county governments, public and state institutions of higher education, independent school districts, city or township governments, special district governments, small businesses, nonprofits non higher education without 501c3, for profit organizations other than small businesses, private institutions of higher education, nonprofits non higher education with 501c3, other
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- PAR-28-022
Program overview
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). Based on the proposed research, applications may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). This is a re-issuance of PAR-23-284 . The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. The research supported through this program must be translational and be based on human biology research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must reach a translational human endpoint within the project period of the grant.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before September 25, 2029, allowing time for registration and validation.
Related grant opportunities
- Collaborative Program Grant for Interdisciplinary Teams (RM1 Clinical Trial Optional)
- SEEDING CRITICAL ADVANCES FOR LEADING ENERGY TECHNOLOGIES WITH UNTAPPED POTENTIAL (SCALEUP) READY
- CHIPS Research and Development Office (CRDO) Broad Agency Announcement (BAA)
- FY 2027 - 2029 Broad Agency Announcement (BAA), Oceanic and Atmospheric Research (OAR)
- Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.